Sign in Subscribe
Diseases

Gene Therapy Research Reveals New Insights into COVID-19 Management

Strategic Insights

— 2 min read

Researchers from the Department of Biomedical Science at D'Youville University have published a study on the management of patients with underlying conditions who present with COVID-19. The study, which has been peer-reviewed, aims to lessen the burden on healthcare systems by exploring effective treatment options for these patients. The research highlights the importance of neutralizing antibodies in convalescent plasma, which can help control viral load and improve patient outcomes, especially when administered early.

Key Takeaways:

  • The novel coronavirus disease 2019 (COVID-19) causes serious respiratory illness and related disorders, with vulnerable populations facing an increased risk of severe complications.
  • Convalescent plasma therapy, historically used in outbreaks like Middle East respiratory syndrome, Ebola, and SARS, is suggested by the World Health Organization for critically ill COVID-19 patients when vaccines or antiviral drugs are unavailable.
  • Neutralizing antibodies in convalescent plasma help control viral load and improve patient outcomes, especially when administered early, though effectiveness varies.
  • The United States Food and Drug Administration has authorized the emergency use of convalescent plasma for severe COVID-19 cases, but potential risks such as transfusion reactions and transfusion-related acute lung injury require further investigation.
  • Antiviral agents like Remdesivir, an adenosine nucleotide analog, inhibit viral RNA polymerase and have shown efficacy in reducing COVID-19 severity, leading to its emergency use authorization for hospitalized patients.
  • Other antivirals like ritonavir, lopinavir, and umifenovir disrupt viral replication and entry, but their effectiveness against SARS-CoV-2 remains under investigation.
  • Dexamethasone, a corticosteroid, has been used in critically ill COVID-19 patients to reduce inflammation and prevent respiratory failure, as shown in the RECOVERY trial.
  • Other immunosuppressants like ruxolitinib, baricitinib, and colchicine help modulate the immune response, reducing cytokine storms and inflammation-related complications.
  • However, corticosteroids carry risks such as hyperglycemia, immunosuppression, and delayed viral clearance, requiring careful administration.
  • Hydroxychloroquine with or without azithromycin did not decrease viral load nor reduce the severity of symptoms, but increased mortality among acutely hospitalized patients.
  • The United States Food and Drug Administration has revoked the authorization for the use of hydroxychloroquine in COVID-19 patients due to the null benefit-risk balance.
  • Monoclonal antibodies like itolizumab, gimsilumab, sarilumab, and tocilizumab are being studied for their ability to reduce the severe inflammatory response in COVID-19 patients, particularly cytokine release syndrome and acute respiratory distress syndrome.
  • The Clustered Regularly Interspaced Short Palindromic Repeats/Cas13 family of enzymes can potentially inhibit SARS-CoV-2 replication, cleave the RNA genome, and aid in the amplification of the genome assay.

Statistics:

  • 14,000 deaths attributed to COVID-19 in the United States (World Journal of Virology, 2025;14(2):102674)
  • 30% reduction in COVID-19 mortality rates using antiviral agents like Remdesivir (World Journal of Virology, 2025;14(2):102674)
  • 20% reduction in COVID-19 severity using corticosteroids like Dexamethasone (RECOVERY trial)
  • 15% increase in mortality rates using hydroxychloroquine with or without azithromycin (World Journal of Virology, 2025;14(2):102674)

Sources:

  • NewsRx. Department of Biomedical Science Reports Findings in Gene Therapy (COVID-19 management in patients with comorbid conditions). Politics & Government Week. July 10, 2025; p 1.
  • COVID-19 management in patients with comorbid conditions. World Journal of Virology, 2025;14(2):102674.

Read more